Search results

2636 results

Sorted by Date . Sort by Relevance

  1. The percentage of patients with a new diagnosis of depression or anxiety and a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 12 months, who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded.

    The percentage of patients with a new diagnosis of depression or anxiety and a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 12 months, who

  2. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses with a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 12 months who have received a brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded.

    The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses with a FAST score of ≥3 or AUDIT-C score of ≥5 in the...

  3. In those patients with a new diagnosis of depression and assessment of severity recorded between the preceding 1 April to 31 March, the percentage of patients who have had a further assessment of severity 2–12 weeks (inclusive) after the initial recording of the assessment of severity. Both assessments should be completed using an assessment tool validated for use in primary care

    NICE indicators. NM11 depression guidance.

  4. The percentage of women with schizophrenia, bipolar affective disorder or other psychoses under the age of 45 years who have been given information and advice about pregnancy, conception or contraception tailored to their pregnancy and contraceptive intentions recorded in the preceding 12 months.

    The percentage of women with schizophrenia, bipolar affective disorder or other psychoses under the age of 45 years who have been given information...

  5. Breast cancer mortality rates

    Breast cancer mortality rates Subject(s): Cancer, Mortality NICE identity code: CCG04

  6. Episcissors-60 show promise for mediolateral episiotomy. But there is currently not enough evidence to support the case for routine adoption in the NHS. Research is recommended to address uncertainties about the efficacy and safety of using Episcissors-60. This research should: - determine if using Episcissors-60 in addition to other care bundle measures is more effective in achieving an optimal episiotomy angle and in preventing episiotomy-related obstetric anal sphincter injuries (OASI) than standard episiotomy scissors - include patient-reported outcome measures - address potential equality considerations by ensuring patients at greatest risk of OASI are recruited - determine the relative cost of using Episcissors-60 compared with standard episiotomy scissors.

    Recommendation ID MTG47/1 Question Episcissors-60 show promise for mediolateral episiotomy. But there is currently not enough evidence

  7. The committee noted that there was no clinical evidence showing that having patiromer improved length or quality of life or allowed patients to stay on optimal doses of renin-angiotensin-aldosterone system (RAAS) inhibitors. It therefore considered that it would be valuable to have studies comparing patiromer plus standard care with standard care alone in people with confirmed hyperkalaemia of 6.0 mmol/litre and above, and that these should investigate: - mortality- disease progression- patterns of RAAS inhibitor use- healthcare utilisation and- health-related quality of life. The committee recalled that the DIAMOND trial is ongoing and may help to provide evidence on mortality (see section 3.11). However, the trial is not going to complete until 2022. The committee concluded that the guidance should be reviewed when evidence from DIAMOND is available.

    Recommendation ID TA623/1 Question The committee noted that there was no clinical evidence showing that having patiromer improved length